Q-omics provides the consensus-scored ACTL8 profile across patient tissues and cancer cell-line models. ACTL8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACTL8 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ACTL8 RNA expression shows 9,457 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where ACTL8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTL8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTL8 survival associations across molecular data types. ACTL8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTL8 RNA expression–survival associations across cancer types. High ACTL8 expression shows unfavorable associations in KIRC, HNSC, UCEC, KIRP, UVM and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACTL8 RNA expression.
This table summarizes ACTL8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ACTL8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTL8 shows higher tumor expression in HNSC, LUAD, BRCA, KIRP, LUSC and LIHC. The HNSC box plot shows higher ACTL8 RNA expression in tumor versus normal tissue (log2 FC = +1.220, t-test p < 0.001).
This table shows molecular features associated with ACTL8 in patient tissues and cancer cell lines. In patient samples, ACTL8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ACTL8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
